Artelo Biosciences, Inc.

NasdaqCM:ARTL Stock Report

Market Cap: US$4.7m

Artelo Biosciences Past Earnings Performance

Past criteria checks 0/6

Artelo Biosciences's earnings have been declining at an average annual rate of -4.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually.

Key information

-4.59%

Earnings growth rate

20.67%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth raten/a
Return on equity-201.81%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Aug 16

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Nano-cap stock Artelo Biosciences (NASDAQ:ARTL) added ~21% in the morning hours Tuesday after the clinical-stage pharma announced the recent publication of preclinical data supporting the potential of its FABP inhibitor therapeutic platform in anxiety-related disorders. The research led by academics Taygun C. Uzuneser, Ph.D., and Steven R. Laviolette, Ph.D., at the University of Western Ontario, London, Ontario, is based on one of Artelo’s (ARTL) FABP inhibitors. As published in the journal Cerebral Cortex, the pre-clinical indicate that a fatty acid binding protein 5 (FABP5) inhibitor from ARTL’s FABP inhibitor platform lessens the anxiety behaviors in a section of the brain important for anxiety. In addition, the research highlights the prospects of modulation of the FABP5 system as a target in developing novel anxiolytics. “This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder,” Chief Executive of Artelo (ARTL) Gregory D. Gorgas noted. Read: A pre-clinical data readout supporting its product candidate ART27.13 sent ARTL shares sharply higher in April.
Analysis Article • Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 09

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for an effective treatment. Phase Ia/Ib clinical trial of Artelo’s ART27.13 compound is fully enrolled and final data could be available for year-end 2022, providing proof of efficacy among cancer patients suffering from anorexia. Capital raise in late 2021 has provided sufficient capital resources to support Artelo through the completion of the required Phase II clinical trials for its ART27.13. Using potential competitors and peers with publicly traded stock to provide comparable valuation metrics, ARTL is found to have intrinsic value well above its current stock price.
Analysis Article • Nov 02

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 12

Relief For Cancer Patients In Artelo Bioscience Pipeline

Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body. To economically build portfolio value, Artelo’s business model relies on both in-licensed and internally developed compounds and contracts for clinical services. Patents awarded to Artelo protect two promising small molecule candidates and a cocrystal of cannabidiol. Human clinical trials are underway for a therapeutic candidate targeting cancer-related anorexia, a worrisome condition that has no established treatment and a market value expected to grow near 10% CAGR through 2030. Artelo has sufficient capital resources to reach its next value-generating milestone at the end of the Phase 1b/2a clinical trial for cancer-related anoxia therapy. Favorable clinical trial data could serve as strong valuation catalyst.
Analysis Article • May 20

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 04

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Revenue & Expenses Breakdown

How Artelo Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ARTL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-1375
31 Dec 250-1365
30 Sep 250-1257
30 Jun 250-1146
31 Mar 250-1046
31 Dec 240-1046
30 Sep 240-946
30 Jun 240-1047
31 Mar 240-1046
31 Dec 230-946
30 Sep 230-1055
30 Jun 230-955
31 Mar 230-1065
31 Dec 220-1064
30 Sep 220-1376
30 Jun 220-1376
31 Mar 220-1266
31 Dec 210-1266
30 Nov 210-954
31 Aug 210-753
31 May 210-742
28 Feb 210-532
30 Nov 200-532
31 Aug 200-532
31 May 200-432
29 Feb 200-432
30 Nov 190-322
31 Aug 190-221
31 May 190-221
28 Feb 190-211
30 Nov 180-311
31 Aug 180-211
31 May 180-211
28 Feb 180-111
30 Nov 170-100
31 Aug 170000
31 May 170000
28 Feb 170000
30 Nov 160000
31 Aug 160000
31 May 160000
29 Feb 160000
30 Nov 150000

Quality Earnings: ARTL is currently unprofitable.

Growing Profit Margin: ARTL is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ARTL is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare ARTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).

Return on Equity

High ROE: ARTL has a negative Return on Equity (-201.81%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 20:53
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artelo Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group